Unsolved problems and future perspectives of hepatitis B virus vaccination

World Journal of Gastroenterology

Volumn 21, Issue 23, 2015, Pages 7074-7083

  Tajiri, Kazuto ^a   Shimizu, Yukihiro ^b  

^a TOYAMA UNIVERSITY HOSPITAL   (Japan)

^b Nanto Municipal Hospital   (Japan)

Author keywords

Escape mutant; Hepatitis B virus vaccination; Immunology; Non responder; Universal vaccination

Indexed keywords

ADJUVANT; HEPATITIS B VACCINE; HLA ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VITRONECTIN; HEPATITIS B SURFACE ANTIGEN; PROTEIN PRECURSOR;

ARTICLE; DNA POLYMORPHISM; DRUG EFFICACY; HEALTH PROGRAM; HEPATITIS B; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; REGULATORY T LYMPHOCYTE; VACCINATION; ADVERSE EFFECTS; DRUG EFFECTS; GENETICS; GENOTYPE; HEPATITIS B VIRUS; IMMUNIZATION; IMMUNOLOGY; MUTATION; PHENOTYPE; TREATMENT OUTCOME; VIROLOGY;

GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION SCHEDULE; MUTATION; PHENOTYPE; PROTEIN PRECURSORS; TREATMENT OUTCOME; VACCINATION;

EID: 84937907903     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i23.7074     Document Type: Article

References (108)

1. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25 Suppl 1: 3-8 [PMID: 16103976 DOI: 10.1055/s-2005-915644]
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343 DOI: 10.1046/j.1365-2893.2003.00487.x]
3. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156 [PMID: 11668491 DOI: 10.1002/ijc.1440]
4. Leung N. Chronic hepatitis B in Asian women of childbearing age. Hepatol Int 2009; 3 Suppl 1: 24-31 [PMID: 19669243 DOI: 10.1007/s12072-009-9142-1]
5. Xu DZ, Yan YP, Choi BC, Xu JQ, Men K, Zhang JX, Liu ZH, Wang FS. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002; 67: 20-26 [PMID: 11920813 DOI: 10.1002/jmv.2187]
6. Bai H, Zhang L, Ma L, Dou XG, Feng GH, Zhao GZ. Relationship of hepatitis B virus infection of placental barrier and hepatitis B virus intra-uterine transmission mechanism. World J Gastroenterol 2007; 13: 3625-3630 [PMID: 17659715 DOI: 10.3748/wjg.v13.i26.3625]
7. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994; 170: 1418-1423 [PMID: 7995980 DOI: 10.1093/infdis/170.6.1418]
8. Li XM, Shi MF, Yang YB, Shi ZJ, Hou HY, Shen HM, Teng BQ. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol 2004; 10: 3215-3217 [PMID: 15457579]
9. Li XM, Yang YB, Hou HY, Shi ZJ, Shen HM, Teng BQ, Li AM, Shi MF, Zou L. Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol 2003; 9: 1501-1503 [PMID: 12854150]
10. Deng M, Zhou X, Gao S, Yang SG, Wang B, Chen HZ, Ruan B. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. Virol J 2012; 9: 185 [PMID: 22947333 DOI: 10.1186/1743-422x-9-185]
11. Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM, Yue X, Wang GJ. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012; 10: 520-526 [PMID: 22343511 DOI: 10.1016/j.cgh.2012.01.019]
12. Romano' L, Paladini S, Van Damme P, Zanetti AR. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig Liver Dis 2011; 43 Suppl 1: S2-S7 [PMID: 21195368 DOI: 10.1016/S1590-8658(10)60685-8]
13. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981; 1: 377-385 [PMID: 7030902 DOI: 10.1002/hep.1840010502]
14. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307: 178-180 [PMID: 6318124 DOI: 10.1038/307178a0]
15. Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 1990; 8 Suppl: S69-S73; discussion S79-S80 [PMID: 2139287]
16. Availability of hepatitis B vaccine that does not contain thimerosal as a preservative. MMWR Morb Mortal Wkly Rep 1999; 48: 780-782
17. Young MD, Schneider DL, Zuckerman AJ, Du W, Dickson B, Maddrey WC. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine. Hepatology 2001; 34: 372-376 [PMID: 11481622 DOI: 10.1053/jhep.2001.26167]
18. Mahoney FJ, Woodruff BA, Erben JJ, Coleman PJ, Reid EC, Schatz GC, Kane MA. Effect of a hepatitis B vaccination program on the prevalence of hepatitis B virus infection. J Infect Dis 1993; 167: 203-207 [PMID: 8418167 DOI: 10.1093/infdis/167.1.203]
19. Rendi-Wagner P, Kundi M, Stemberger H, Wiedermann G, Holzmann H, Hofer M, Wiesinger K, Kollaritsch H. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001; 19: 2055-2060 [PMID: 11228377 DOI: 10.1016/S0264-410X(00)00410-2]
20. Abraham B, Parenti D. Antibody production in response to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. J Infect Dis 2000; 182: 1005-1006 [PMID: 10950809 DOI: 10.1086/315745]
21. Jackson Y, Chappuis F, Mezger N, Kanappa K, Loutan L. High immunogenicity of delayed third dose of hepatitis B vaccine in travellers. Vaccine 2007; 25: 3482-3484 [PMID: 17306910 DOI: 10.1016/j.vaccine.2006.12.053]
22. Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr Infect Dis J 1993; 12: 438-445 [PMID: 8327313 DOI: 10.1097/00006454-199305000-00037]
23. Hoofnagle JH. Toward universal vaccination against hepatitis B virus. N Engl J Med 1989; 321: 1333-1334 [PMID: 2529440 DOI: 10.1056/NEJM198911093211910]
24. Hepatitis B. Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en/
25. Immunization Coverage. Available from: URL: http://www.who.int/mediacentre/factsheets/fs378/en/
26. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigenpositive mothers. Cochrane Database Syst Rev 2006; (2): CD004790 [PMID: 16625613 DOI: 10.1002/14651858.CD004790.pub2]
27. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, Kao JH, Lin YC, Chen HL, Hsu HY, Chen DS. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007; 132: 1287-1293 [PMID: 17433322 DOI: 10.1053/j.gastro.2007.02.055]
28. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859 [PMID: 9197213 DOI: 10.1056/NEJM199706263362602]
29. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-1355 [PMID: 19759364 DOI: 10.1093/jnci/djp288]
30. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012; 57: 730-735 [PMID: 22668640 DOI: 10.1016/j.jhep.2012.05.021]
31. Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R, Whittle HC. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 1999; 17: 2946-2950 [PMID: 10462228 DOI: 10.1016/S0264-410X(99)00178-4]
32. van der Sande MA, Waight P, Mendy M, Rayco-Solon P, Hutt P, Fulford T, Doherty C, McConkey SJ, Jeffries D, Hall AJ, Whittle HC. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 2006; 193: 1528-1535 [PMID: 16652281 DOI: 10.1086/503433]
33. McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M, Homan C, Parkinson AJ. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011; 54: 801-807 [PMID: 21618565 DOI: 10.1002/hep.24442]
34. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, Bulkow L, Fiore AE, Bell BP, Hennessy TW. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009; 200: 1390-1396 [PMID: 19785526 DOI: 10.1086/606119]
35. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ 2009; 58: 1-27 [PMID: 19478727]
36. Ng KP, Saw TL, Baki A, Rozainah K, Pang KW, Ramanathan M. Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol 2005; 194: 163-168 [PMID: 15834754 DOI: 10.1007/s00430-004-0231-4]
37. Bonanni P, Pesavento G, Bechini A, Tiscione E, Mannelli F, Benucci C, Nostro AL. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 2003; 21: 685-691 [PMID: 12531340 DOI: 10.1016/S0264-410X(02)00580-7]
38. Mele A, Tosti ME, Mariano A, Pizzuti R, Ferro A, Borrini B, Zotti C, Lopalco P, Curtale F, Balocchini E, Spada E. Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges. Clin Infect Dis 2008; 46: 868-875 [PMID: 18269332 DOI: 10.1086/528687]
39. Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain JP, Gerlich W. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011; 364: 236-247 [PMID: 21247314 DOI: 10.1056/NEJMoa1007644]
40. Lai MW, Lin TY, Tsao KC, Huang CG, Hsiao MJ, Liang KH, Yeh CT. Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination. Gastroenterology 2012; 143: 400-407 [PMID: 22580098 DOI: 10.1053/j.gastro.2012.05.002]
41. Wu TW, Lin HH, Wang LY. Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology 2013; 57: 37-45 [PMID: 22858989 DOI: 10.1002/hep.25988]
42. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998; 15: 1-8 [PMID: 9651632 DOI: 10.1016/S0749-3797(98)00003-8]
43. Albayrak A, Ertek M, Tasyaran MA, Pirim I. Role of HLA allele polymorphism in chronic hepatitis B virus infection and HBV vaccine sensitivity in patients from eastern Turkey. Biochem Genet 2011; 49: 258-269 [PMID: 21188498 DOI: 10.1007/s10528-010-9404-6]
44. Mert G, Sengul A, Gul HC, Karakas A, Eyigun CP. The role of human leukocyte antigen tissue groups in hepatitis B virus vaccination in Turkey. J Microbiol Immunol Infect 2014; 47: 9-14 [PMID: 23523043 DOI: 10.1016/j.jmii.2013.01.004]
45. Vitaliti G, Praticò AD, Cimino C, Di Dio G, Lionetti E, La Rosa M, Leonardi S. Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow. World J Gastroenterol 2013; 19: 838-845 [PMID: 23430309 DOI: 10.3748/wjg.v19.i6.838]
46. Yoon JH, Shin S, In Jw, Chang JY, Song EY, Roh EY. Association of HLA alleles with the responsiveness to hepatitis B virus vaccination in Korean infants. Vaccine 2014; 32: 5638-5644 [PMID: 25148772 DOI: 10.1016/j.vaccine.2014.08.007]
47. Li ZK, Nie JJ, Li J, Zhuang H. The effect of HLA on immunological response to hepatitis B vaccine in healthy people: a meta-analysis. Vaccine 2013; 31: 4355-4361 [PMID: 23887040 DOI: 10.1016/j.vaccine.2013.06.108]
48. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004; 39: 978-988 [PMID: 15057902 DOI: 10.1002/hep.20142]
49. Duan Z, Chen X, Liang Z, Zeng Y, Zhu F, Long L, McCrae MA, Zhuang H, Shen T, Lu F. Genetic polymorphisms of CXCR5 and CXCL13 are associated with non-responsiveness to the hepatitis B vaccine. Vaccine 2014; 32: 5316-5322 [PMID: 25077417 DOI: 10.1016/j.vaccine.2014.07.064]
50. Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 2008; 19: 600-604 [PMID: 18725550 DOI: 10.1258/ijsa.2007.007197]
51. del Pozo Balado Mdel M, Leal M, Méndez Lagares G, Mata RC, López-Cortés LF, Viciana P, Pacheco YM. Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. J Infect Dis 2010; 202: 362-369 [PMID: 20560766 DOI: 10.1086/653707]
52. Shi L, Wang JM, Ren JP, Cheng YQ, Ying RS, Wu XY, Lin SM, Griffin JW, Li GY, Moorman JP, Yao ZQ. KLRG1 impairs CD4+ T cell responses via p16ink4a and p27kip1 pathways: role in hepatitis B vaccine failure in individuals with hepatitis C virus infection. J Immunol 2014; 192: 649-657 [PMID: 24337749 DOI: 10.4049/jimmunol.1302069]
53. Wang JM, Ma CJ, Li GY, Wu XY, Thayer P, Greer P, Smith AM, High KP, Moorman JP, Yao ZQ. Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection. Vaccine 2013; 31: 2238-2245 [PMID: 23499521 DOI: 10.1016/j.vaccine.2013.03.003]
54. Tan KL, Goh KT, Oon CJ, Chan SH. Immunogenicity of recombinant yeast-derived hepatitis B vaccine in nonresponders to perinatal immunization. JAMA 1994; 271: 859-861 [PMID: 8114241 DOI: 10.1001/jama.1994.03510350069039]
55. Rangel MC, Coronado VG, Euler GL, Strikas RA. Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Semin Dial 2000; 13: 101-107 [PMID: 10795113 DOI: 10.1046/j.1525-139x.2000.00029.x]
56. McDermott AB, Cohen SB, Zuckerman JN, Madrigal JA. Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response - evidence for genetic basis in humans. J Viral Hepat 1998; 5 Suppl 2: 9-11 [PMID: 9857354 DOI: 10.1046/j.1365-2893.1998.0050s2009.x]
57. Krawczyk A, Ludwig C, Jochum C, Fiedler M, Heinemann FM, Shouval D, Roggendorf M, Roggendorf H, Lindemann M. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. Vaccine 2014; 32: 5077-5082 [PMID: 24975813 DOI: 10.1016/j.vaccine.2014.06.076]
58. Hellström UB, Madalinski K, Sylvan SP. PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac vaccine and their relation to the antibody response to hepatitis B surface antigen. Virol J 2009; 6: 7 [PMID: 19154574 DOI: 10.1186/1743-422X-6-7]
59. Sylvan SP, Madalinski K, Hellström UB. Anti-preS responses influence the anti-HBs response in newborns after vaccination with the third generation Sci-B-Vac vaccine. Vaccine 2009; 28: 446-451 [PMID: 19874926 DOI: 10.1016/j.vaccine.2009.10.023]
60. Lankarani KB, Talebzadeh M, Eshraghian A, Malek-Hosseini SA. Granulocyte colony stimulating factor adjuvant role on the immunological response to hepatitis B vaccine in patients with cirrhosis: a double blind randomized placebo controlled trial. Hepat Mon 2014; 14: e15447 [PMID: 24910704 DOI: 10.5812/hepatmon.15447]
61. Lin C, Zhu J, Zheng Y, Chen Y, Wu Z, Chong Y, Gao Z. Effect of GM-CSF in combination with hepatitis B vaccine on revacination of healthy adult non-responders. J Infect 2010; 60: 264-270 [PMID: 20138189 DOI: 10.1016/j.jinf.2010.01.011]
62. Fabrizi F, Ganeshan SV, Dixit V, Martin P. Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in endstage renal disease. Aliment Pharmacol Ther 2006; 24: 789-796 [PMID: 16918882 DOI: 10.1111/j.1365-2036.2006.03035.x]
63. Overton ET, Sungkanuparph S, Klebert M, Royal M, Demarco-Shaw D, Powderly WG, Aberg JA. GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. Open Virol J 2011; 5: 109-113 [PMID: 22043256 DOI: 10.2174/1874357901105010109]
64. Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 1994; 344: 856-857 [PMID: 7916403 DOI: 10.1016/S0140-6736(94)92829-0]
65. Mauri JM, Vallès M. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Collaborative Group of Girona. Nephrol Dial Transplant 1997; 12: 729-732 [PMID: 9141002 DOI: 10.1093/ndt/12.4.729]
66. Fabrizi F, Dixit V, Martin P, Messa P. Hepatitis C virus and the immunological response to hepatitis B virus vaccine in dialysis patients: meta-analysis of clinical studies. J Viral Hepat 2011; 18: 871-876 [PMID: 22093033 DOI: 10.1111/j.1365-2893.2011.01459.x]
67. Alavian SM, Tabatabaei SV. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials. Clin Ther 2010; 32: 1-10 [PMID: 20171406 DOI: 10.1016/j.clinthera.2010.01.005]
68. Tong NK, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, Vilella A, de Juanes JR, Arrazola P, Calbo-Torrecillas F, de Novales EL, Hamtiaux V, Lievens M, Stoffel M. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005; 68: 2298-2303 [PMID: 16221232 DOI: 10.1111/j.1523-1755.2005.00689.x]
69. Kong NC, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, Vilella A, Calbo-Torrecillas F, López de Novales E, Srinivasa K, Stoffel M, Hoet B. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008; 73: 856-862 [PMID: 18160963 DOI: 10.1038/sj.ki.5002725]
70. Tielemans CL, Vlasak J, Kosa D, Billiouw JM, Verpooten GA, Mezei I, Ryba M, Peeters PC, Mat O, Jadoul MY, Polakovic V, Dhaene M, Treille S, Kuriyakose SO, Leyssen M, Houard SA, Surquin M. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials. Vaccine 2011; 29: 1159-1166 [PMID: 21167859 DOI: 10.1016/j.vaccine.2010.12.009]
71. Yasumura S, Shimizu Y, Yasuyama T, Hiroki O, Okada K, Tsukishiro T, Tsuchida T, Higuchi K, Watanabe A. Intradermal hepatitis B virus vaccination for low- or non-responded health-care workers. Acta Med Okayama 1991; 45: 457-459 [PMID: 1838229]
72. Das HS, Sawant P, Shirhatti RG, Vyas K, Vispute S, Dhadphale S, Patrawalla V, Desai N. Efficacy of low dose intradermal hepatitis B vaccine: results of a randomized trial among health care workers. Trop Gastroenterol 2002; 23: 120-121 [PMID: 12693152]
73. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12: 1204-1211 [PMID: 9198052 DOI: 10.1093/ndt/12.6.1204]
74. Playford EG, Hogan PG, Bansal AS, Harrison K, Drummond D, Looke DF, Whitby M. Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. Infect Control Hosp Epidemiol 2002; 23: 87-90 [PMID: 11894838 DOI: 10.1086/502012]
75. Levitz RE, Cooper BW, Regan HC. Immunization with highdose intradermal recombinant hepatitis B vaccine in healthcare workers who failed to respond to intramuscular vaccination. Infect Control Hosp Epidemiol 1995; 16: 88-91 [PMID: 7759824 DOI: 10.2307/30140948]
76. Ghebrehewet S, Baxter D, Falconer M, Paver K. Intradermal recombinant hepatitis B vaccination (IDRV) for non-responsive healthcare workers (HCWs). Hum Vaccin 2008; 4: 280-285 [PMID: 18398298 DOI: 10.4161/hv.4.4.5687]
77. Fabrizi F, Dixit V, Messa P, Martin P. Intradermal vs intramuscular vaccine against hepatitis B infection in dialysis patients: a meta-analysis of randomized trials. J Viral Hepat 2011; 18: 730-737 [PMID: 20819147 DOI: 10.1111/j.1365-2893.2010.01354.x]
78. Barraclough KA, Wiggins KJ, Hawley CM, van Eps CL, Mudge DW, Johnson DW, Whitby M, Carpenter S, Playford EG. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis 2009; 54: 95-103 [PMID: 19481320 DOI: 10.1053/j.ajkd.2009.03.010]
79. Chanchairujira T, Chantaphakul N, Thanwandee T, Ong-Ajyooth L. Efficacy of intradermal hepatitis B vaccination compared to intramuscular vaccination in hemodialysis patients. J Med Assoc Thai 2006; 89 Suppl 2: S33-S40 [PMID: 17044452]
80. Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis 2012; 12: 966-976 [PMID: 23174382 DOI: 10.1016/S1473-3099(12)70243-8]
81. Leonardi S, Praticò AD, Lionetti E, Spina M, Vitaliti G, La Rosa M. Intramuscular vs intradermal route for hepatitis B booster vaccine in celiac children. World J Gastroenterol 2012; 18: 5729-5733 [PMID: 23155313 DOI: 10.3748/wjg.v18.i40.5729]
82. Filippelli M, Lionetti E, Gennaro A, Lanzafame A, Arrigo T, Salpietro C, La Rosa M, Leonardi S. Hepatitis B vaccine by intradermal route in non responder patients: an update. World J Gastroenterol 2014; 20: 10383-10394 [PMID: 25132754 DOI: 10.3748/wjg.v20.i30.10383]
83. Wu JS, Hwang LY, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis 1999; 179: 1319-1325 [PMID: 10228050 DOI: 10.1086/314768]
84. Zanetti AR, Mariano A, Romanò L, D'Amelio R, Chironna M, Coppola RC, Cuccia M, Mangione R, Marrone F, Negrone FS, Parlato A, Zamparo E, Zotti C, Stroffolini T, Mele A. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366: 1379-1384 [PMID: 16226616 DOI: 10.1016/S0140-6736(05)67568-X]
85. Chaves SS, Fischer G, Groeger J, Patel PR, Thompson ND, Teshale EH, Stevenson K, Yano VM, Armstrong GL, Samandari T, Kamili S, Drobeniuc J, Hu DJ. Persistence of long-term immunity to hepatitis B among adolescents immunized at birth. Vaccine 2012; 30: 1644-1649 [PMID: 22245310 DOI: 10.1016/j.vaccine.2011.12.106]
86. Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, Su IJ, Kuo HS, Huang LM, Chen DS, Lee CY. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008; 197: 1419-1426 [PMID: 18444799 DOI: 10.1086/587695]
87. Jan CF, Huang KC, Chien YC, Greydanus DE, Davies HD, Chiu TY, Huang LM, Chen CJ, Chen DS. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 2010; 51: 1547-1554 [PMID: 20209603 DOI: 10.1002/hep.23543]
88. Wiström J, Ahlm C, Lundberg S, Settergren B, Tärnvik A. Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. Vaccine 1999; 17: 2162-2165 [PMID: 10367949 DOI: 10.1016/S0264-410X(99)00012-2]
89. Propst T, Propst A, Lhotta K, Vogel W, König P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998; 32: 1041-1045 [PMID: 9856522 DOI: 10.1016/S0272-6386(98)70081-2]
90. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355: 561-565 [PMID: 10683019 DOI: 10.1016/S0140-6736(99)07239-6]
91. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, Melzer JS, Roberts JP, Tomlanovich SJ, Vincenti F. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59: 230-234 [PMID: 7839446 DOI: 10.1097/00007890-199501270-00014]
92. Zanetti AR, Tanzi E, Manzillo G, Maio G, Sbreglia C, Caporaso N, Thomas H, Zuckerman AJ. Hepatitis B variant in Europe. Lancet 1988; 2: 1132-1133 [PMID: 2460710 DOI: 10.1016/S0140-6736(88)90541-7]
93. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-329 [PMID: 1697396 DOI: 10.1016/0140-6736(90)91874-A]
94. Ogata N, Zanetti AR, Yu M, Miller RH, Purcell RH. Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant. J Infect Dis 1997; 175: 511-523 [PMID: 9041321 DOI: 10.1093/infdis/175.3.511]
95. Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997; 26: 786-791 [PMID: 9303514 DOI: 10.1002/hep.510260336]
96. Zuckerman AJ. Effect of hepatitis B virus mutants on efficacy of vaccination. Lancet 2000; 355: 1382-1384 [PMID: 10791517 DOI: 10.1016/S0140-6736(00)02132-2]
97. Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 2004; 53: 1499-1503 [PMID: 15361503 DOI: 10.1136/gut.2003.034223]
98. Hsu HY, Chang MH, Ni YH, Chiang CL, Chen HL, Wu JF, Chen PJ. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis 2010; 201: 1192-1200 [PMID: 20210630 DOI: 10.1086/651378]
99. Luongo M, Critelli R, Grottola A, Gitto S, Bernabucci V, Bevini M, Vecchi C, Montagnani G, Villa E. Acute hepatitis B caused by a vaccine-escape HBV strain in vaccinated subject: sequence analysis and therapeutic strategy. J Clin Virol 2015; 62: 89-91 [PMID: 25542480 DOI: 10.1016/j.jcv.2014.11.029]
100. Wilson JN, Nokes DJ, Carman WF. The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern? Vaccine 1999; 17: 973-978 [PMID: 10067705 DOI: 10.1016/S0264-410X(98)00313-2]
101. Kramvis A, Kew M, François G. Hepatitis B virus genotypes. Vaccine 2005; 23: 2409-2423 [PMID: 15752827 DOI: 10.1016/j.vaccine.2004.10.045]
102. Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 2003; 46: 329-338 [PMID: 14688448 DOI: 10.1159/000074988]
103. Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res 2010; 40: 14-30 [PMID: 20156297 DOI: 10.1111/j.1872-034X.2009.00601.x]
104. Matsuura K, Tanaka Y, Hige S, Yamada G, Murawaki Y, Komatsu M, Kuramitsu T, Kawata S, Tanaka E, Izumi N, Okuse C, Kakumu S, Okanoue T, Hino K, Hiasa Y, Sata M, Maeshiro T, Sugauchi F, Nojiri S, Joh T, Miyakawa Y, Mizokami M. Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol 2009; 47: 1476-1483 [PMID: 19297602 DOI: 10.1128/JCM.02081-08]
105. Cassidy A, Mossman S, Olivieri A, De Ridder M, Leroux-Roels G. Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity. Expert Rev Vaccines 2011; 10: 1709-1715 [PMID: 22085174 DOI: 10.1586/erv.11.151]
106. Hamada-Tsutsumi S, Iio E, Watanabe T, Murakami S, Isogawa M, Iijima S, Inoue T, Matsunami K, Tajiri K, Ozawa T, Kishi H, Muraguchi A, Joh T, Tanaka Y. Validation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infection. PLoS One 2015; 10: e0118062 [PMID: 25693196 DOI: 10.1371/journal.pone.0118062]
107. Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ, Huang FC, Wu SF, Chen SC, Wen WH, Chu CH, Ni YH, Hsu HY, Tsai PL, Chiang CL, Shyu MK, Lee PI, Chang FY, Chang MH. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 2012; 142: 773-781.e2 [PMID: 22198276 DOI: 10.1053/j.gastro.2011.12.035]
108. Shi Z, Li X, Ma L, Yang Y. Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother-to-child transmission-a meta-analysis. Int J Infect Dis 2010; 14: e622-e634 [PMID: 20106694 DOI: 10.1016/j.ijid.2009.09.008]